Medical Devices · Healthcare
CEO, Board Member
2020-01-01–present
Board Member
Delcath Systems, Inc. (DCTH)Equibles does not estimate personal net worth.
Get an email with a short summary when Delcath Systems, Inc. publishes a filing, an earnings call transcript or a press release.
Get DCTH alertsGerard Michel is recorded as Board Member at Delcath Systems, Inc. (DCTH) since January 1, 2020 and CEO at Delcath Systems, Inc. (DCTH). The newest filing on record that lists Gerard Michel as CEO and Board Member at Delcath Systems, Inc. (DCTH) is dated April 2, 2026. Earlier roles on record: CFO at Vericel Corp (VCEL) until September 30, 2020. Delcath Systems, Inc. reported in an 8-K filed May 16, 2025 a re-election or new board role (Class I director) for Gerard Michel, on the board since at least 2020, effective May 15, 2025. The proxy statement of Delcath Systems, Inc. reports total compensation of $5,765,258 for Gerard Michel in fiscal 2025, including a base salary of $635,707. Disclosed compensation is on record for 8 fiscal years. Gerard Michel has spoken on 24 earnings calls across 2 companies, most recently for Delcath Systems, Inc. on November 9, 2026. Those appearances were for Delcath Systems, Inc. (DCTH) and Vericel Corp (VCEL). Delcath Systems, Inc. is classified in the Medical Devices industry within the Healthcare sector. Other companies whose calls Gerard Michel spoke on are classified in the Healthcare sector. Other leadership on record at Delcath Systems, Inc. includes John Purpura (CEO), Sandra Pennell (CFO), Martha Rook (COO) and 7 others.
“Stockholders elected the following nominees to serve as Class I directors on the board of directors of the Company (the "Board") until the Company's 2028 Annual Meeting or until their successors have been duly elected and qualified.”
“Delcath's record third quarter of $35.1 million in revenue, up 71% in the third quarter in 2025, reflects the growing adoption of HapsadoKit and the hard work of both the Delcath and Physician Treatment teams.”
“Now well into our third year of commercial launch. We continue to deliver revenue growth and operate as a profitable business, supported by a platform with the potential to address larger patient populations well beyond metastatic uveal melanoma.”
“We've had a very successful first quarter marked by four center activations and record new patient starts in the first quarter, both of which are core growth drivers for the business.”
“2025 was a pivotal year, delivering over 40% volume growth and record revenue of $85.2 million, including $20.7 million in the fourth quarter alone.”
“Thank you for joining us today to review our third quarter financial results and business updates.”
2020-01-01–present
Last confirmed April 2, 2026
Start not stated–present
Last confirmed April 2, 2026
Start not stated–2020-09-30
Medical Devices · Healthcare
CEO, Board Member
2020-01-01–present
VCEL
Biotechnology · Healthcare
CFO
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2025 | Delcath Systems, Inc. (DCTH) | Chief Executive Officer | $635,707 | $5,765,258 |
| 2024 | Delcath Systems, Inc. (DCTH) | Chief Executive Officer | $560,622 | $2,157,414 |
| 2023 | Delcath Systems, Inc. (DCTH) | Chief Executive Officer | $538,078 | $2,520,314 |
| 2022 | Delcath Systems, Inc. (DCTH) | Chief Executive Officer | $521,024 | $1,472,198 |
| 2021 | Delcath Systems, Inc. (DCTH) | Chief Executive Officer | $475,151 | $1,914,402 |
| 2020 | Delcath Systems, Inc. (DCTH) | Chief Executive Officer | $112,500 | $5,761,000 |
| 2020 | Vericel Corp (VCEL) | Former CFO and VP of Corporate Development | $315,385 | $1,614,906 |
| 2019 | Delcath Systems, Inc. (DCTH) | Chief Executive Officer | — | — |
| 2019 | Vericel Corp (VCEL) | Former CFO and VP of Corporate Development | $398,000 | $2,304,701 |
| 2018 | Vericel Corp (VCEL) | Former CFO and VP of Corporate Development | $386,000 | $1,114,773 |